A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Public ClinicalTrials.gov record NCT07224750. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT07224750
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 1,000 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 20, 2024
- Primary completion
- Jun 17, 2026
- Completion
- Jun 17, 2026
- Last update posted
- Nov 25, 2025
2024 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Nat Medical Ctr | Duarte | California | 91010 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Cholangiocarcinoma trials
Other public records listing Cholangiocarcinoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07738939: IKS04 Regimen in Advanced Solid Tumors That Express CA242 Not yet recruiting
- NCT06910670: Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid Recruiting
- NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma Active, not recruiting
- NCT07673341: [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma Not yet recruiting
- NCT07486713: Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Recruiting
- NCT06503146: 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07224750, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 25, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07224750 live on ClinicalTrials.gov.